South Carolina Marijuana News

The stock price for shares in Tilray was up sharply Tuesday on news that the Canadian company will export more of a medicinal cannabis drug to Australia. Shares in Tilray, based in Nanaimo, British Columbia, were up 18.5 percent to $118 in mid-day trading on the NASDAQ stock exchange.

After trading ended on Monday, Tilray announced that it had successfully exported cannabis medication to Australia to treat severely ill children. The medicine, CBD 100, is a cannabidiol extract in an oral solution. The company will distribute it to three hospitals in the state of Victoria through its subsidiary Tilray Australia New Zealand. The medications will be sent to Royal Children’s Hospital, Monash Children’s Hospital, and Austin Health with the support of the Department of Health and Human Services of the state of Victoria. The cannabis drug will be used to treat children with severe forms of epilepsy.

‘Life-Changing Treatment’

Tilray first announced in March that the company had received permission to ship the medicine to Victoria to treat 29 children with intractable epilepsy. At that time, Premier Daniel Andrews said that there was a critical need for the drug.

“This is too important to wait,” Andrews said. “That’s why we’re doing everything we

Read More Here…

Marijuana arrests are rising in the U.S., even as more states legalize cannabis.

There is now an average of one marijuana bust roughly every 48 seconds, according to a new FBI report released on Monday.

The increase in marijuana arrests—659,700 in 2017, compared to 653,249 in 2016—is driven by enforcement against people merely possessing the drug as opposed to selling or growing it, the data shows.

Last year, there were 599,282 marijuana possession arrests in the country, up from 587,516 in 2016. Meanwhile, busts for cannabis sales and manufacturing dropped, from 65,734 in 2016 to 60,418 in 2017.

– Read the entire article at Forbes.

Read More Here…

The cannabis industry is in desperate need of trained workers as legalization looms.

British Columbia’s Okanagan College has a mandate to serve the interests of businesses in its community. So when licensed cannabis producer Sunniva started building a greenhouse and manufacturing facility in the region, the company reached out to the school in the hopes of forming a partnership. Sunniva knew it would need to hire 200-plus employees for their launch in 2019 and they wanted them specially trained — people who understood the plant biology, the production cycles and the business of cannabis.

Normally, Okanagan creates new courses using information provided by the government to determine what kind of workers are needed and what classes should focus on, but in the fast-moving cannabis industry that wasn’t an option. Instead, the college created an advisory board with their partners to hear straight from the companies themselves — Sunniva and Crop Health, a local crop consulting service — what skills they needed.

– Read the entire article at News.

Read More Here…

The internet was agog at skyrocketing cannabis stock prices last week. And while those have been fluctuating, jobs and salaries in the legal marijuana industry have been climbing steadily as states continue to legalize medical or recreational use. Cannabis jobs are on the rise and salaries are increasing, according to a new report by the California-based employment agency Vangst. Those figures are set to grow further as capital continues to flow into the industry and the work force gains experience.

Vangst, founded in 2015, has connected about 7,500 job seekers with the emerging legal weed industry. Recently the company surveyed 1200 cannabis companies, to find out who they’re hiring and how much they are paying. Vangst added information it has collected in its day-to-day operations to those survey results to put together a cannabis salary guide. Vangst CEO Karson Humiston, said the industry is rapidly outpacing other US job area growth.

Others in the industry echo the sentiment. “Growth of the marijuana industry has been extraordinary in every sense,” said Jon Fanburg, an attorney at the New Jersey law firm Brach Eichler. He was one of nearly 800 attendees at a bidder’s conference for six new medical cannabis sales licenses

Read More Here…

It used to be a very simple question to answer: How many medical marijuana states are there?

Before the election of President Barack Obama, you either lived in a state where patients with certain conditions could legally grow and use cannabis as medicine with a doctor’s recommendation, or you lived in a state where growing cannabis got you thrown in prison—no matter what your condition.

Since then, however, there have been more-restrictive medical marijuana laws passed in some states. Some states don’t let patients (or their caregivers) cultivate their own cannabis, forcing them to the dispensary to purchase medicine. Some states don’t allow cannabis flower at all, relegating patients to only non-smoked forms of medicine.

Then there is the recent advent of states, mostly in the South and Midwest, that allow low-THC / high-CBD cannabis oils, primarily for epileptic children. Are these so-called “CBD-only states” to be considered “medical marijuana states,” when nobody is using any actual marijuana? What about the states lacking smokable cannabis flower, a.k.a. marijuana? Are those “medical marijuana states?”

The major national marijuana reform organizations take different views on the question. Americans for Safe Access (ASA), the non-profit focused exclusively on medical cannabis reforms, takes the

Read More Here…

Cannabidiol (CBD) may prevent haloperidol-induced orofacial dyskinesia, according  to new research being published by the journal Brain, Behavior, and Immunity; the research was epublished by the National Institute of Health.

“The chronic use of drugs that reduce the dopaminergic neurotransmission can cause a hyperkinetic movement disorder called tardive dyskinesia (TD)”, states the study’s abstract. “The pathophysiology of this disorder is not entirely understood but could involve oxidative and neuroinflammatory mechanisms. Cannabidiol (CBD), the major non-psychotomimetic compound present in Cannabis sativa plant, could be a possible therapeutic alternative for TD.”

The study states that “This phytocannabinoid shows antioxidant, anti-inflammatory and antipsychotic properties and decreases the acute motor effects of classical antipsychotics. The present study investigated if CBD would attenuate orofacial dyskinesia, oxidative stress and inflammatory changes induced by chronic administration of haloperidol in mice.”

Furthermore, researchers “verified in vivo and in vitro (in primary microglial culture) whether these effects would be mediated by PPARγ receptors. The results showed that the male Swiss mice treated daily for 21 days with haloperidol develop orofacial dyskinesia. Daily CBD administration before each haloperidol injection prevented this effect.”

Mice treated with haloperidol “showed an increase in microglial activation and inflammatory mediators in the striatum. These changes were also reduced by

Read More Here…

Judges in Seattle have agreed to clear past misdemeanor convictions for marijuana possession that were prosecuted before marijuana was legalized in Washington, reports the Seattle Times.

All seven judges of the Seattle Municipal Court have signed an order setting out a process for vacating the cases. The ruling follows City Attorney Pete Holmes’ filing of a motion in April asking the court to vacate the convictions.

In his motion, Holmes argued that possessing small amounts of marijuana is no longer illegal and clearing past convictions would right the injustices of a drug war that targeted people of color.

About 542 people could be affected. The ruling covers from about 1996 – when municipal courts, rather than county district courts, began handling those misdemeanors – to 2010 when Holmes became city attorney and stopped prosecuting low-level, non-violent marijuana cases.

“Insomuch as the conduct for which the defendant was convicted is no longer criminal, setting aside the conviction and dismissing the case serves the interests of justice,” wrote the judges in their ruling.

Read More Here…

A Maine restaurant that had been sedating lobsters with cannabis before boiling them alive is now under investigation for the culinary preparation, according to media reports. Charlotte Gill, the owner of Charlotte’s Legendary Lobster Pound in Southwest Harbor, Maine, had been offering the option to patrons ordering live Maine lobster at the restaurant.

But state regulators have taken notice and now the Maine Health Inspection Program is investigating the practice, a spokesperson for the Department of Health and Human Services has confirmed.

Gill is a registered medical marijuana caregiver and grows the cannabis she uses for the lobster. But a spokesman for the Maine Medical Marijuana program, David Heidrich, said in an email that the use of cannabis was not appropriate.

“Medical marijuana may only be grown for and provided to persons with a marijuana recommendation from a qualified medical provider,” he said. “Lobsters are not people.”

Temporarily Off the Menu

The restaurant has temporarily stopped selling the “high-end lobster,” as Gill calls it, but she hopes to be able to offer it again.

“After being contacted by the state, and upon reviewing its present laws and codes applicable to this arena, and then making a few minor adjustments to our procedure, we are

Read More Here…

Cannabinoids may provide a potential treatment option for prostate cancer, according to a new study published by the journal The Prostate.

“Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer”, states researchers. In the present study, they “explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.”

For the study, “Established prostate cancer cells (PC3, DU145, LNCaP) were treated with varying concentrations of WIN”, and “Cell proliferation was determined by the MTS assay.” The anti-migration and anti-invasive potential of WIN “was examined by the wound healing assay and the matrigel invasion assay.” Cell cycle analysis was performed by flow cytometry, and mechanistic studies were performed by Western blot.

Animals were randomized into two groups: saline control and WIN (5 mg/kg), delivered by intraperitoneal injection three times per week for 3 weeks.

“WIN significantly reduced prostate cancer cell proliferation, migration, invasion, induced apoptosis, and arrested cells in Go/G1 phase in a dose-dependent manner”, claim researchers.

They conclude; “The following study provides evidence supporting the use of WIN as a novel therapeutic for prostate cancer.”

For more info on this study, click here.

Read More Here…